Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OIG on medical supplier fraud

This article was originally published in The Gray Sheet

Executive Summary

An HHS Office of Inspector General 1report released March 3 finds persisting problems in Medicare compliance among suppliers of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS), including hospital beds, wheelchairs and artificial limbs. OIG inspected 905 suppliers in Los Angeles County, one of the "hotspots" of supplier problems, and found in addition to other violations that 13% of suppliers did not have a physical facility or were closed during repeated visits. OIG recommends that CMS conduct more unannounced site visits, increase prepayment reviews of DMEPOS claims, and establish minimum inventory requirements for product types. CMS says it has already addressed a number of the identified fraud vulnerabilities (2"The Gray Sheet" July 9, 2007, p. 14)

You may also be interested in...



CMS Targets Fraud Among DME Suppliers In Florida, Los Angeles

All durable medical equipment suppliers in three counties in South Florida and four in the Los Angeles area will have to reapply for CMS-855S numbers that allow them to bill Medicare for beneficiaries' DME, prosthetics, orthotics and other medical supplies. The effort is part of a demonstration project launched by CMS July 2

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel